COMPANY
Infusion Options, Inc.
Infusion Options, Inc.: recalling firm for Carfilzomib, Oxytocin, as stated by public registers.
RECALLING FIRM
Recalled a product naming the peptide (FDA enforcement report).
| Carfilzomib | Class II recall, Terminated, 2019-08-21 Regulator openFDA |
|---|---|
| Oxytocin | Class II recall, Terminated, 2019-08-21 Regulator openFDA |
What a register states, not an endorsement or an accusation by this site. All companies.
WEEKLY
Register Watch, weekly
New trials, approvals and enforcement actions. One email a week.